IL31 and breast angiosarcoma: This case highlights the potential role of IL-31 in cholestatic pruritus and suggests that IL-31 blockade with nemolizumab may be an effective therapeutic option for refractory pruritus in pediatric patients with BA, warranting further investigation into its broader clinical applications beyond AD.